5946-39-4

Usage

Uses

Used in Pharmaceutical Research:
2,3,4,5-Tetrahydro-1H-benzo[E][1,4]diazepine is used as a research compound for exploring its chemical properties and potential interactions with biological systems. Its unique structure allows researchers to investigate its role in the development of new pharmaceutical agents.
Used as a Precursor in Synthesis:
In the chemical industry, 2,3,4,5-Tetrahydro-1H-benzo[E][1,4]diazepine is utilized as a precursor in the synthesis of a variety of biologically active compounds. Its presence in these compounds can contribute to their therapeutic effects and potential applications in medicine.
Used in Drug Discovery and Development:
2,3,4,5-Tetrahydro-1H-benzo[E][1,4]diazepine is employed as a target molecule in drug discovery and development processes. Its structure and properties make it a promising candidate for the creation of new drugs with potential therapeutic applications.
Used in Therapeutic Applications:
2,3,4,5-Tetrahydro-1H-benzo[E][1,4]diazepine is used as an anticonvulsant agent for the treatment of seizure disorders. Its chemical properties may help to modulate neuronal activity and reduce the frequency and severity of seizures.
2,3,4,5-Tetrahydro-1H-benzo[E][1,4]diazepine is also used as an anxiolytic agent for the treatment of anxiety disorders. Its potential to interact with neurotransmitter systems may help to alleviate symptoms of anxiety and promote a sense of calm and well-being.

InChI:InChI=1/C9H12N2/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10-11H,5-7H2

Upstream product

• 28544-83-4 1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-5-one 
• 5118-94-5 1,4-benzodiazepine-2,5-dione 
• 118-48-9 isatoic anhydride 
• 1824-72-2 1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one 
• 179686-64-7 methyl N-(2-nitrobenzyl)glycinate 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 88-72-2 1-methyl-2-nitrobenzene 
• 107468-24-6 2-Methyl-2-chinolyl-azid 
• 32112-94-0 4-quinolyl azide 
• 21352-22-7 3-amino-2-methylquinoline 
• 5973-34-2 (2-aminobenzoylamino)acetic acid ethyl ester 
• 114627-59-7 3-Methoxy-2-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepine 
• 107468-28-0 3-Methoxy-2-methyl-3H-benzo[e][1,4]diazepine 
• 1086096-22-1 2-chloro-N-(2-nitrobenzyl)ethanamine 

Downstream Products

• 195983-63-2 2,3,4,5-Tetrahydro-4-[(1,1-dimethylethoxy)-carbonyl]-1H-1,4-benzodiazepine 
• 1027571-29-4 2-(1,2,3,5-tetrahydro-benzo[e][1,4]diazepine-4-sulfonyl)-benzoic acid methyl ester 
• 57756-36-2 4-Acetyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin 
• 5163-19-9 4-methyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine 
• 620948-92-7 4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij] quinoline 
• 620948-77-8 Benzyl 1,2,3,5-tetrahydro-4H-1,4-benzodiazepine-4-carboxylate 

Relevant academic research and scientific papers

IDH1 mutant micromolecule inhibitor, and preparation method and application thereof

The invention discloses an IDH1 mutant micromolecule inhibitor, and a preparation method and application thereof. The structure of the inhibitor is as shown in a formula I, and the definition of the substituent groups is as described in the specification

Synthesis and Structure-Activity Relationships of Tool Compounds Based on WAY163909, a 5-HT2C Receptor Agonist

The development of probe molecules that can be used to investigate G protein-coupled receptor (GPCR) pharmacology, trafficking, and relationship with other GPCRs is an important and growing area of research. Here, we report the synthesis of analogues of t

Design, synthesis, and pharmacological evaluation of fused β-homophenylalanine derivatives as potent DPP-4 inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors are accepted as a favorable class of agents for the treatment of type 2 diabetes. Herein, a series of fused β-homophenylalanine derivatives as novel DPP-4 inhibitors were designed, synthesized, and evaluated for their inhibitory activities against DPP-4. Most of them displayed excellent DPP-4 inhibitory activities and good selectivity. Among them, 9aa, 18a, and 18m also showed good efficacy in an oral glucose tolerance test (OGTT) in ICR mice. Moreover, when dosed 8 h prior to glucose challenge, 18m showed significantly greater potency than sitagliptin. It thus provides potential candidates for the further development into potent drugs targeting DPP-4.

PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES

The present invention relates to a process for preparing 4-acetyl-2,3,4,5-tetrahydrobenzo[1,4]diazepine and the intermediates thereof. The present invention provides a compound represented by formula I and a compound represented by formula II, and processes for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine by using the compound represented by formula I, the compound represented by formula II and o-nitrobenzaldehyde. The invention has the advantages of the shorter synthesis steps, easily available raw materials and simple operation. Moreover, the process is economic and safe by avoiding the use of expensive and dangerous lithium aluminium hydride.

Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof

The present invention relates to a process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof. The present invention provides a compound represented by formula I and a compound represented by formula II, and proces

Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT 2C receptor

Evaluation of selected compounds from our Corporate Compound Library in a human 5-HT2C receptor binding assay led to the discovery of WAY-629, a cyclohexyl[b][1,4]benzodiazepinoindole (Ki 56nM, Emax 90%), which is selectiv

Inhibitors of farnesyl protein transferase

The present invention comprises benzodiazepine compounds having farnesyl transferase inhibitory activity.

Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase

2,3,4,5-Tetrahydro-1-(imidazol-4-ylalkyl)-1,4-benzodiazepines were found to be potent inhibitors of farnesyltransferase (FT). A hydrophobic substituent at the 4-position of the benzodiazepine, linked via a hydrogen bond acceptor, was important to enzyme i

Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N- methyltransferase

In the search for potent and selective inhibitors of the enzyme phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28), we examined the effect of ring size or an additional heteroatom in the conformationally- restricted benzylamine-type PNMT inhibitors. Based on semiempirical calculations (MNDO) and molecular modeling studies, PNMT-inhibitory activity of these compounds seemed to be dependent on (a) the torsion angle between the plane of the aromatic ring and the endo N atom lone pair (τ2 angle), with the optimal value of τ2 being about -75°, and (b) the amount of steric bulk about the 3-position of 1,2,3,4-tetrahydroisoquinoline (5, THIQ). 2,3,4,5-Tetrahydro-1H-2-benzazepine (6) was found to have the highest selectivity (PNMT K(i) = 3.34 μM, α2 K(i) = 11 μM, selectivity = 3.2) as compared to other homologues of THIQ (PNMT K(i) = 9.67 μM, α2 K(i) = 0.35 μM, selectivity = 0.036). The higher PNMT-inhibitory activity of 6 was attributed to favorable steric interactions of the puckered methylene groups in the putative bioactive conformation of 6 at the PNMT active site, whereas unfavorable interactions of these puckered methylene groups at the α2- adrenoceptor were thought to be the cause of reduced α2 affinity of 6. No further enhancement of the selectivity of the benzazepine ring system could be obtained via introduction of a second heteroatom (N, O, S) at the 5- position in this ring system.

Studies on Diazepines. XXIX. Syntheses of 3H- and 5H-1,4-Benzodiazepines from 3-Azidoquinolines

Irradiation of the 3-azidoquinolines (6a-c) in the presence of sodium methoxide resulted in ring expansion to give the fully unsaturated 3-methoxy-3H-1,4-benzodiazepines (8).Further treatment of the 2-unsubstituted 3H-1,4-benzodiazepine (8a) with sodium methoxide in methanol gave the solvent adduct 7, which reverted to 8a on being refluxed in benzene, whereas the 2-substituted 3H-1,4-benzodiazepines (8b, c), upon treatment with sodium methoxide, underwent tautomerization to afford the 5H-1,4-benxodiazepines (15).Some reactions of the new 1,4-benzodiazepines (8 and 15) thus obtained were also examined.Keywords--3-azidoquinoline; 3H-1,4-benzodiazepine; 5H-1,4-benzodiazepine; photolysis; ring expansion; tautomerization; base treatment; quinolylnitrene